Recent Research Analysts’ Ratings Changes for Krystal Biotech (KRYS)

Krystal Biotech (NASDAQ: KRYS) recently received a number of ratings updates from brokerages and research firms:

  • 11/4/2026 – Krystal Biotech was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
  • 11/3/2026 – Krystal Biotech had its price target lowered by Citigroup from $416.00 to $412.00. They now have a “buy” rating on the stock.
  • 11/3/2026 – Krystal Biotech had its price target lowered by TD Cowen from $403.00 to $380.00. They now have a “buy” rating on the stock.
  • 11/3/2026 – Krystal Biotech had its price target lowered by Royal Bank Of Canada from $400.00 to $375.00. They now have an “outperform” rating on the stock.
  • 10/23/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
  • 10/23/2026 – Krystal Biotech was downgraded by Zacks Research from “hold” to “strong sell”.
  • 10/15/2026 – Krystal Biotech had its “buy” rating reaffirmed by Citigroup.
  • 10/15/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $361.00 price target on the stock.
  • 10/9/2026 – Krystal Biotech was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
  • 9/24/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
  • 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group. They set a “buy” rating and a $441.00 price target on the stock.
  • 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group. They set a “buy” rating and a $441.00 price target on the stock.
  • 9/23/2026 – Krystal Biotech was upgraded by William Blair to “strong-buy”.
  • 9/21/2026 – Krystal Biotech had its price target raised by Bank of America from $392.00 to $400.00. They now have a “buy” rating on the stock.

Krystal Biotech Stock Down 0.6%

Shares of Krystal Biotech stock traded down $1.82 on Tuesday, hitting $296.07. 43,284 shares of the company traded hands, compared to its average volume of 325,094. Krystal Biotech, Inc. has a 12-month low of $202.99 and a 12-month high of $382.54. The company has a market cap of $8.77 billion, a PE ratio of 40.17 and a beta of 0.56. The company has a 50-day moving average price of $325.55 and a 200 day moving average price of $309.83.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The firm had revenue of $127.34 million during the quarter, compared to analysts’ expectations of $125.77 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 7.74 EPS for the current year.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

Read More

Receive News & Ratings for Krystal Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.